Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

This study is testing a radioactive treatment called lutetium-177 PSMA (Lu-PSMA) in men with advanced prostate cancer that no longer responds to hormone therapy — including men with varying levels of kidney function. **You may be eligible if:** - You have prostate cancer that has spread and is no longer responding to hormone therapy (called mCRPC) - Your PSMA scan is positive - Your testosterone level is very low (castrate level) - Your cancer is progressing based on rising PSA, new bone lesions, or tumor growth **You may NOT be eligible if:** - You have previously received PSMA-targeted radioactive therapy - You have recently received certain bone-targeting radioactive treatments (e.g., Radium-223) - You have severe urinary obstruction or incontinence - You have significant heart rhythm problems - You are taking medications that prolong the heart's QT interval Talk to your doctor to see if this trial is right for you.